Form 4: Assembly Biosciences CMO Receives RSU Grant
Statement of Changes in Beneficial Ownership
Chief Medical Officer Anuj Gaggar acquired 14,000 restricted stock units following stockholder approval of an equity plan amendment.
Summary
- Anuj Gaggar, Chief Medical Officer of Assembly Biosciences, Inc., was granted 14,000 restricted stock units (RSUs).
- The grant represents 35% of the officer's annual equity award.
- The issuance was contingent upon the June 4, 2026, stockholder approval of an amendment to the 2018 Stock Incentive Plan.
- The RSUs vest in four equal annual installments starting March 29, 2027, through March 29, 2030.
- The reporting person also acquired 688 shares via the Employee Stock Purchase Plan on May 14, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and does not indicate a change in company performance or outlook.
Positives
- Alignment of executive compensation with long-term shareholder interests through multi-year RSU vesting.
- Successful passage of the 2018 Stock Incentive Plan amendment by stockholders.
Negatives
- None identified in this filing.
Risks
- Vesting of equity is contingent upon the reporting person's continuous service to the company.
Future Outlook
The reporting person's equity will vest annually over a four-year period, contingent upon continued employment.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice for retention and performance alignment, particularly following the expansion of authorized share pools.
Comparison to Industry Standards
- The use of four-year vesting schedules for RSU grants is consistent with standard corporate governance practices for US-listed biotech firms.
- The reliance on stockholder approval for plan amendments aligns with typical regulatory requirements for equity incentive plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Plan Amendment | Stockholders approved an amendment to the 2018 Stock Incentive Plan to increase authorized shares. | 06/04/2026 | Allows for continued issuance of equity-based compensation to employees and directors. |
Stakeholder Impact
- Shareholders: Dilution impact is mitigated by the approved increase in the share pool.
- Employees: Continued access to equity incentive programs.
Next Steps
- Vesting of the first tranche of RSUs on March 29, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/29/2026 | Date of RSU grant approval and initial transaction date. |
| 05/14/2026 | Date of ESPP share acquisition. |
| 06/04/2026 | Stockholder approval of the Plan Amendment. |
| 06/05/2026 | Filing date of the Form 4. |
| 03/29/2027 | First vesting date for the RSU grant. |
Keywords
ASMB, Assembly Biosciences, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.